Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-15
2008-01-15
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254090, C514S323000, C514S414000, C544S144000, C544S373000, C546S208000, C548S518000
Reexamination Certificate
active
07319098
ABSTRACT:
The present invention relates to 1,3-dioxoisoindole derivatives of Formula (1) or pharmaceutically acceptable salts thereof, a preparation method thereof and use thereof as a T-type calcium channel antagonist, based on the fact that 1,3-dioxoisoindole derivatives of Formula (1) show selective antagonistic activity against T-type calcium channel, thus being effective in treating brain diseases, cardiac diseases and neurogenic pains:wherein R1is a phenyl or a benzyl group, optionally substituted with a moiety selected from the group consisting of a halogen atom, a C1-C6alkoxy, a C1-C6alkyl, and a cyano group; R2is a heterocyclic group selected from the group consisting of piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl groups, wherein the heterocyclic group is optionally substituted with a C1-C6alkyl group; and n is 1 or 2.
REFERENCES:
NINDS Alzheimer's Disease Information page, retrieved from Internet on Apr. 5, 2007, <http://www.ninds.nih.gov/disorders/alzheimersdisease/alzheimersdisease.htm>.
Selkoe, Alzheimer's Disease: Genes, Proteins, and Therapy, Apr. 2001, Physiological Reviews, vol. 81(2), 741-766.
Nelson et al, Role of T-type Clacium Channels in Epilepy and Pain, 2006, Current Pharmaceutical Design, 12, p. 2189-2197.
Hosravani, Houman et al., “Effects of Ca3.2 channel mutations linked to idiopathic generalized epilepsy”, Annals of Neurology (2005), 57(5), 745-749.
Vitko, Iuliia et al., “Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of CACNA1H, a T-type calcium channel”, Journal of Neuroscience (2005), 25(19), 4844-4855.
Clozel et al.,Cardiovas Drugs Ther.(1990), 4, pp. 731-736.
Hefti et al.,Arzneimittelforschung(1990), 40, 417-421.
Moosmang, Sven et al., “Antihypertensive Effects of the Putative T-Type Calcium Channel Antagonist Mibefradil are Mediated by the L-Type Calcium Channel Cav1.2”, Circulation Research (2006), 98(1), 105-110.
Flatters, Sarah J.L., “T-type calcium channels: A potential target for the treatment of chronic pain”, Drugs of the Future (2005), 30(6), 573-580.
Barton, Matthew E. et al., “The antyhyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil”, European Journal of Pharmacology (2005), 521(1-3), 79-85.
Flatters, Sarah J.L. et al., “Ethosuximide reverses paclitaxel- and vincristine- induced painful peripheral neuropathy”, Pain (2004), 109(1-2), 150-161.
Dogrul, Ahmet et al., “Reversal of experimental neuropathic paid by T-type calcium channel blockers”, Pain (2003), 105(1-2), 159-168.
Cha Joo Hwan
Cho Yong Seo
Choo Hyunah
Kim Hwa-Sil
Koh Hun Yeong
Anderson Rebecca
Cheng Karen
Frommer & Lawrence & Haug LLP
Korea Institute of Science and Technology
Santucci Ronald R.
LandOfFree
1,3-dioxoisoindole derivatives having selective antagonism... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-dioxoisoindole derivatives having selective antagonism..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-dioxoisoindole derivatives having selective antagonism... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2780419